» Articles » PMID: 2234207

Survival and Mortality in a Randomized Study of Lung Cancer Detection

Overview
Journal Neoplasma
Specialty Oncology
Date 1990 Jan 1
PMID 2234207
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In a randomized prospective study of lung cancer detection in a high-risk population of over 6000 heavy smokers semiannual screening by X-ray and sputum cytology was compared to screening at a 3-year interval. The comparison of Kaplan-Meier estimates of survival curves done without and with correcting for lead-time bias disclosed a rather important impact of lead-time bias on survival comparisons. On the contrary, controlling for possible length bias had no obvious effect on the shape of survival curves. The evaluation of mortality from lung cancer, being used as a basic criterion, indicated no traceable benefit from semiannual screening. The higher incidence of lung cancer in the frequently screened group was paralleled by a higher mortality. It is concluded that currently available screening techniques will not solve the problem of lung cancer mortality in smokers. The results underline the importance of primary prevention for lung cancer.

Citing Articles

Do we know enough about the effect of low-dose computed tomography screening for lung cancer on mortality to act? An updated systematic review, meta-analysis and network meta-analysis of randomised controlled trials 2017 to 2021.

Duer E, Yang H, Robinson S, Grigore B, Sandercock J, Snowsill T Diagn Progn Res. 2023; 7(1):26.

PMID: 38072977 PMC: 10712083. DOI: 10.1186/s41512-023-00162-0.


Deep learning-based diagnosis of lung cancer using a nationwide respiratory cytology image set: improving accuracy and inter-observer variability.

Kim T, Chang H, Kim B, Yang J, Koo D, Lee J Am J Cancer Res. 2023; 13(11):5493-5503.

PMID: 38058836 PMC: 10695775.


Do we know enough about the effect of low-dose computed tomography screening for lung cancer on survival to act? A systematic review, meta-analysis and network meta-analysis of randomised controlled trials.

Yang H, Varley-Campbell J, Coelho H, Long L, Robinson S, Snowsill T Diagn Progn Res. 2020; 3:23.

PMID: 31890897 PMC: 6933743. DOI: 10.1186/s41512-019-0067-4.


Improvement of survival for non-small cell lung cancer over time.

Xia W, Yu X, Mao Q, Xia W, Wang A, Dong G Onco Targets Ther. 2017; 10:4295-4303.

PMID: 28919778 PMC: 5587133. DOI: 10.2147/OTT.S145036.


Screening for lung cancer.

Manser R, Lethaby A, Irving L, Stone C, Byrnes G, Abramson M Cochrane Database Syst Rev. 2013; (6):CD001991.

PMID: 23794187 PMC: 6464996. DOI: 10.1002/14651858.CD001991.pub3.